14,271 Shares in Amedisys, Inc. (NASDAQ:AMED) Purchased by Strs Ohio

Strs Ohio bought a new position in Amedisys, Inc. (NASDAQ:AMED) during the fourth quarter, Holdings Channel reports. The firm bought 14,271 shares of the health services provider’s stock, valued at approximately $1,356,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. purchased a new stake in Amedisys in the 4th quarter valued at about $258,000. Argonautica Private Wealth Management Inc. increased its stake in Amedisys by 6.1% in the 3rd quarter. Argonautica Private Wealth Management Inc. now owns 3,003 shares of the health services provider’s stock valued at $280,000 after buying an additional 172 shares during the last quarter. MRP Capital Investments LLC purchased a new stake in Amedisys in the 3rd quarter valued at about $337,000. Commonwealth Equity Services LLC increased its stake in Amedisys by 2.9% in the 3rd quarter. Commonwealth Equity Services LLC now owns 3,896 shares of the health services provider’s stock valued at $364,000 after buying an additional 110 shares during the last quarter. Finally, Xponance Inc. increased its stake in Amedisys by 3.2% in the 3rd quarter. Xponance Inc. now owns 4,076 shares of the health services provider’s stock valued at $381,000 after buying an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on AMED. Raymond James reiterated a “market perform” rating on shares of Amedisys in a research note on Tuesday, March 26th. StockNews.com started coverage on shares of Amedisys in a research note on Monday, April 8th. They issued a “buy” rating for the company. Finally, Royal Bank of Canada raised their price target on shares of Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 25th. Seven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $97.50.

Amedisys Trading Up 0.9 %

Shares of AMED stock opened at $91.24 on Tuesday. The company has a 50 day moving average of $92.72 and a 200-day moving average of $93.40. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 0.32. Amedisys, Inc. has a 12-month low of $73.10 and a 12-month high of $96.44. The firm has a market cap of $2.98 billion, a P/E ratio of -294.31, a PEG ratio of 4.25 and a beta of 0.86.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, February 21st. The health services provider reported $0.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.10). The company had revenue of $570.79 million for the quarter, compared to analysts’ expectations of $566.85 million. Amedisys had a positive return on equity of 12.76% and a negative net margin of 0.44%. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.16 EPS. Sell-side analysts anticipate that Amedisys, Inc. will post 4.54 earnings per share for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.